 |
 |
I'm forwarding this for a former PD Net Member, He is a journalist in Holland (Netherlands). BTW, I have the pleasure of running the 4th.floor at the library today (Sunday) so I won't be home until late, if any of you want to email me about this report. As Ever, Marjorie Moorefield just another librarian, with PD Date: Sun, 13 Apr 1997 10:35:04 -0400 >From: Hein ten Bosch <[log in to unmask]> >Subject: Cabaser - New drug for UK >To: Marjorie Moorefield <[log in to unmask]> > >Dear Marjorie >Can you do me a favor? It seems Brian Collins is not completely informed. >The story is different. Can you please copy the real story to the list for >me? > >Subject: Cabaser - New drug for UK >Brian apparently only has part of the story. The full narration is this: >Cabergoline was invented years ago by Italian pharmaceutical Farmitalia, a >company acquired by Upjohn. Many years ago Cabergoline arrived on the >European market (apparently NOT in the UK) as Dostinex, a product for >breastfeeding mothers to temper the flux and finally stop the breastfeed. >It works very good for that purpose and brings Upjohn a lot of money, as it >is expensive. >Once a product is registered for a certain application (in most European >countries), it is forbidden to register it for another ailment or >application under different name. Upjohn would have to take Dostinex from >the market to re-introduce it as Cabaser for helping against Parkinson. But >Dostinex brings a lot of dough. >And that is how it is. >Thanks for your time >Hein ten Bosch > >